Trading Signals: TGTX Stock Price Prediction and Forecast (Mon. Aug. 10, 2015 - Wed. Sep. 14, 2022)(TG Therapeutics Inc)
| TGTX latest price $17.9800 (2.8%) ($17.9800 - $17.9800) on Thu. Jan. 6, 2022. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 6.24% (three month average) | RSI | 65 | Latest Price | $17.9800(2.8%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | TGTX declines -1.5% a day on average for past five trading days. | Weekly Trend | TGTX advances 3.3% a week on average for past two weeks. | Market Behavior | Normal for large cap. Value stock rally for small cap. | Correlated ETFs | Broad market will support TGTX advance at 0% a week (0% probability) XBI(75%) ARKG(69%) IBB(67%) ARKK(64%) IWO(62%) | Factors Impacting TGTX price | TGTX will decline at least -3.12% in a week (0% probabilities). VIXM(-47%) VXX(-39%) UUP(-25%) UNG(-7%) USO(-5%) | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -3.12% (StdDev 6.24%) | Hourly BBV | -0.9 () | Intraday Trend | 0% | | | |
|
Resistance Level | $18.01 | 5 Day Moving Average | $18.85(-4.62%) | 10 Day Moving Average | $18.97(-5.22%) | 20 Day Moving Average | $18.01(-0.17%) | To recent high | -49.5% | To recent low | 18.4% | Market Cap | $2.277b | | | | TG Therapeutics, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1101, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in New York, NY. |